Reviewed by Sarah Alter, Ph.D. — Scientific Affairs, OrganaBio. 15 years of immunology research spanning autoimmunity, cancer, and infectious disease. University of Miami Miller School of Medicine. Registered Patent Agent.
COPD is characterized by progressive airflow limitation driven by chronic airway inflammation, emphysema, and small airway remodeling. While the disease is centered in the lung, peripheral blood immune populations from COPD donors carry the systemic inflammatory signature of the disease: elevated CD8+ cytotoxic T cells, altered innate immune activation, and NK cell dysfunction patterns that are increasingly relevant to pipeline candidates targeting systemic COPD inflammation rather than only bronchodilation.
Systemic Immune Biology in COPD
CD8+ T cells are the dominant adaptive immune population in COPD lung tissue, and their peripheral counterparts in PBMC preparations show elevated cytotoxic activation and altered migration patterns. Neutrophilic inflammation is the hallmark of the airways (not well captured by PBMCs, which lack circulating neutrophils at meaningful frequency), but monocyte activation and macrophage polarization priming are detectable in peripheral blood and are relevant to anti-IL-1β, anti-IL-33, and anti-TSLP pipeline programs. NK cell subsets show altered cytotoxicity in COPD, and PBMC-derived NK cells are used in mechanistic studies of barrier innate immunity relevant to COPD exacerbation biology.
OrganaBio COPD Donor Catalog
| Attribute | Available |
|---|---|
| COPD severity (GOLD stage) | GOLD I–IV documented on select lots |
| Smoking history | Pack-year history documented; current vs. former smoker noted |
| Exacerbation history | Available on select lots (frequent exacerbator phenotype) |
| Treatment status | ICS/LABA, LAMA, phosphodiesterase inhibitors documented |
| PBMC format | Cryopreserved; fresh on scheduled collection |
| Lot documentation | CoA, GOLD stage, smoking history, medications, flow cytometry |
Key Cell Populations for COPD Research
- CD8+ cytotoxic T cells: Dominant adaptive population in COPD lung; expanded and activated in peripheral blood; CD8+ T cell elastase and perforin/granzyme pathways drive emphysema
- CD4+ Th1 cells: IFN-γ production elevated in systemic COPD inflammation; co-elevated with CD8+ T cell activation
- Classical and non-classical monocytes: Chronic monocyte activation (CD16+/CD14+ non-classical expansion) is a peripheral marker of COPD systemic inflammation; IL-1β production from activated monocytes is a therapeutic target
- NK cells: Altered cytotoxicity in COPD; relevant to anti-viral immunity and exacerbation biology; NK cell subset proportions shift with smoking history and GOLD stage
- ILC2s: Elevated in eosinophilic COPD overlap phenotypes; IL-33 and TSLP pathway activation; relevant to anti-ILC2 biologics in COPD with T2 inflammation
Research Applications
- Systemic inflammation profiling: CD8+ T cell activation, monocyte subset analysis, and cytokine secretion in COPD PBMCs stratified by GOLD stage
- Anti-IL-1β and anti-IL-33 target engagement assays: monocyte and ILC2 response in COPD PBMCs
- Anti-TSLP mechanism studies: ILC2 and Th2 responses in COPD donors with eosinophilic overlap phenotype
- NK cell dysfunction characterization relevant to COPD exacerbation and anti-viral innate immunity
- Smoking history comparison: smoking-associated immune activation vs. non-smoking COPD donors for deconvoluting tobacco vs. disease-driven effects
- Biomarker validation: peripheral CD8+ T cell activation markers (CD38, HLA-DR, granzyme B) as systemic COPD severity surrogates
